Potential treatment for polymorphic light eruption A 2010 phase III, randomized, double blind, placebo controlled, parallel group study was undertaken in Germany, the Netherlands, and Belgium to evaluate the safety and efficacy of subcutaneous implants of melanotan I (16 mg) in patients suffering from polymorphic light eruption (PLE), a condition characterized by a rash following exposure to sunlight
You may experience transient nausea, constipation, or mild fatigue as your caloric intake drops
We use small needles and careful technique to make the experience as comfortable as possible
WEBSITE TRICARE Members Call for TRICARE Beneficiary Customer Service or Technical Support for the TRICARE Beneficiary Program
For counting, each condition was plated in triplicate